Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment - PubMed (original) (raw)
Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment
M J Hurley et al. Brain Res. 1996.
Abstract
The distribution of the dopamine D3 receptor was studied by receptor autoradiography using [3H]7-OH-DPAT in striatal and extrastriatal brain regions of the common marmoset (Callithrix jacchus). Saturation studies demonstrated that [3H]7-OH-DPAT bound with similar affinity to different regions of marmoset brain. In normal marmosets, specific [3H]7-OH-DPAT binding was found in both striatal and extrastriatal regions. Very high levels of specific [3H]7-OH-DPAT binding were detected in the islands of Calleja and nucleus accumbens but in addition high levels of binding were detected in rostral caudate nucleus and putamen. In common marmosets treated with the selective nigral neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the levels of specific [3H]7-OH-DPAT binding in striatal and extrastriatal regions were not different to those in normal animals. Chronic treatment of MPTP-treated marmosets with L-DOPA/ carbidopa did not alter the levels of specific [3H]7-OH-DPAT binding in any brain region. These results demonstrate that in common marmosets D3 receptors are located in both striatal and limbic regions. The receptor density is not altered by dopaminergic denervation or by chronic L-DOPA administration. The D3 receptor may, therefore, be important in both the therapeutic and adverse effects of drugs used to treat Parkinson's disease.
Similar articles
- Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD. Gnanalingham KK, et al. Synapse. 1993 Jun;14(2):184-94. doi: 10.1002/syn.890140212. Synapse. 1993. PMID: 8332947 - Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernández-Ruiz JJ. Lastres-Becker I, et al. Eur J Neurosci. 2001 Dec;14(11):1827-32. doi: 10.1046/j.0953-816x.2001.01812.x. Eur J Neurosci. 2001. PMID: 11860478 - Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N, Jourdain VA, Morissette M, Grégoire L, Di Paolo T. Morin N, et al. Neuropharmacology. 2014 Apr;79:688-706. doi: 10.1016/j.neuropharm.2014.01.014. Epub 2014 Jan 20. Neuropharmacology. 2014. PMID: 24456747 - 5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review.
Kwan C, Frouni I, Bédard D, Nuara SG, Gourdon JC, Hamadjida A, Huot P. Kwan C, et al. Exp Brain Res. 2019 Feb;237(2):435-442. doi: 10.1007/s00221-018-5434-9. Epub 2018 Nov 15. Exp Brain Res. 2019. PMID: 30443669 Review. - [Application of the common marmoset to pharmacological studies].
Nomoto M. Nomoto M. Nihon Yakurigaku Zasshi. 1995 Jul;106(1):11-8. doi: 10.1254/fpj.106.11. Nihon Yakurigaku Zasshi. 1995. PMID: 7590519 Review. Japanese.
Cited by
- Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation.
Murer MG, Moratalla R. Murer MG, et al. Front Neuroanat. 2011 Aug 11;5:51. doi: 10.3389/fnana.2011.00051. eCollection 2011. Front Neuroanat. 2011. PMID: 21886608 Free PMC article. - Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.
Cenci MA, Konradi C. Cenci MA, et al. Prog Brain Res. 2010;183:209-33. doi: 10.1016/S0079-6123(10)83011-0. Prog Brain Res. 2010. PMID: 20696322 Free PMC article. - Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review. - Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.
Chagraoui A, Di Giovanni G, De Deurwaerdère P. Chagraoui A, et al. Biomolecules. 2022 Feb 1;12(2):243. doi: 10.3390/biom12020243. Biomolecules. 2022. PMID: 35204744 Free PMC article. Review. - D2 receptors and cognitive flexibility in marmosets: tri-phasic dose-response effects of intra-striatal quinpirole on serial reversal performance.
Horst NK, Jupp B, Roberts AC, Robbins TW. Horst NK, et al. Neuropsychopharmacology. 2019 Feb;44(3):564-571. doi: 10.1038/s41386-018-0272-9. Epub 2018 Nov 15. Neuropsychopharmacology. 2019. PMID: 30487652 Free PMC article.